ArticleJournal of inflammation research2022
Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas.
Article in Journal of inflammation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pan-immune-inflammation value as a novel prognostic biomarker for digestive system cancers: a meta-analysis.World journal of surgical oncology · 2024Pooled it
- Prognostic significance of the pretreatment pan-immune-inflammation value in cancer patients: an updated meta-analysis of 30 studies.Frontiers in nutrition · 2023Pooled it
- Pan-immune-inflammation value as a prognostic and predictive biomarker in metastatic non-small cell lung cancer treated with nivolumab: A real-world study.Oncology letters · 2026Article
- Diagnostic efficacy of pan-immune inflammation value for ulcerative colitis activity: a study based on multi-indicator comparison and diagnostic grey zone validation.BMC gastroenterology · 2026Article
- Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study.Journal of clinical medicine · 2026Article
- Pan-Immune-Inflammation Value as a Novel Predictor of Contrast-Associated Acute Kidney Injury in Patients Treated with Primary PCI for STEMI.Journal of clinical medicine · 2026Article
- Pan-immune-inflammation value predicts 2-year recurrence after chemoradiotherapy in nasopharyngeal carcinoma.Frontiers in medicine · 2026Article
- Pretreatment Pan-Immune-Inflammation Value and Corrected Prognostic Nutritional Index for 24-Month Recurrence Risk Stratification After Neoadjuvant Chemotherapy and Surgery in Stage III Endometrial Cancer.International journal of women's health · 2026Article
- The prognostic importance of the pan-immune-inflammation value (PIV) in lung cancer: a systematic review and meta-analysis.Translational lung cancer research · 2025Article
- The systemic inflammatory response index (SIRI) as a prognostic factor for long-term survival in patients with pancreatic cancer.Biomarkers in medicine · 2025Article
- The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms' tumor patients.BMC cancer · 2025Article
- Correlation between pan immune inflammation value and testosterone deficiency risk increase.Scientific reports · 2025Article
- Association of pan-immune-inflammatory value with metabolic dysfunction-associated steatotic liver disease: findings from NHANES 2017-2020.BMC gastroenterology · 2025Article
- Pan-immune-inflammation value and its association with all-cause and cause-specific mortality in the general population: a nationwide cohort study.Frontiers in endocrinology · 2025Article
- Pan-immune-inflammation value predicts survival in inflammatory breast cancer patients.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Peripheral blood immunoinflammatory biomarkers: prospective predictors of postoperative long-term survival and chronic postsurgical pain in breast cancer.Frontiers in immunology · 2025Article
- Pan-Immune-Inflammation Value as a Novel Prognostic Biomarker for Advanced Pancreatic Cancer.Cureus · 2024Article
- Novel Somay's GLUCAR Index Efficiently Predicts Survival Outcomes in Locally Advanced Pancreas Cancer Patients Receiving Definitive Chemoradiotherapy: A Propensity-Score-Matched Cohort Analysis.Journal of personalized medicine · 2024Article
- Development and internal validation of a nomogram based on peripheral blood inflammatory markers for predicting prognosis in nasopharyngeal carcinoma.Cancer medicine · 2024Article
- Prognostic significance of pan-immune-inflammation value (PIV) in nasopharyngeal carcinoma patients.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study sought to determine whether pretreatment pan-immune-inflammation value (PIV) could be used to predict prognosis in patients with locally advanced pancreatic adenocarcinoma (LA-PAC) following definitive concurrent chemoradiotherapy (C-CRT). Methods: The outcomes of 178 LA-PAC patients who received definitive C-CRT were analyzed retrospectively. For all patients, the PIV was calculated using the peripheral blood platelet (P), monocyte (M), neutrophil (N), and lymphocyte (L) counts obtained on the first day of C-CRT: PIV=P×M×N÷L. The optimum cutoff values for PIV connected to progression-free (PFS) and overall survival (OS) results were sought using receiver operating characteristic (ROC) curve analysis. The OS and PFS differences between the PIV groups constituted the primary and secondary endpoints, respectively. Results: ROC curve analysis indicated that the ideal PIV cutoff was 464 (AUC: 75.9%, sensitivity: 74.1%, specificity: 71.9%), which categorized patients into two groups based on PFS and OS results: low PIV (L-PIV; N = 69) and high PIV (H-PIV; N = 109). According to comparative survival analyses, patients in the L-PIV group had significantly longer median PFS (14.3 vs 7.3 months; HR: 3.04; P<0.001) and OS (25.9 vs 13.3 months; HR: 2.86; P<0.001) than those in the H-PIV group. Although none of the H-PIV patients could survive beyond 5 years, the estimated 5-year OS rate was 29.7% in the L-PIV cohort. In multivariate analyses, besides the L-PIV, N Conclusion: The present results indicated that pre-C-CRT L-PIV measures were associated with favorable median and long-term PFS and OS results in LA-PAC patients, suggesting that the PIV is a potent and independent novel prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.